Biological Sciences Division and Environmental Molecular Sciences Laboratory, Pacific Northwest National Laboratory, Richland, WA 99352, USA.
Proteomics. 2012 Apr;12(8):1074-92. doi: 10.1002/pmic.201100436.
Selected reaction monitoring (SRM) - also known as multiple reaction monitoring (MRM) - has emerged as a promising high-throughput targeted protein quantification technology for candidate biomarker verification and systems biology applications. A major bottleneck for current SRM technology, however, is insufficient sensitivity for, e.g. detecting low-abundance biomarkers likely present at the low ng/mL to pg/mL range in human blood plasma or serum, or extremely low-abundance signaling proteins in cells or tissues. Herein, we review recent advances in methods and technologies, including front-end immunoaffinity depletion, fractionation, selective enrichment of target proteins/peptides including posttranslational modifications, as well as advances in MS instrumentation which have significantly enhanced the overall sensitivity of SRM assays and enabled the detection of low-abundance proteins at low- to sub-ng/mL level in human blood plasma or serum. General perspectives on the potential of achieving sufficient sensitivity for detection of pg/mL level proteins in plasma are also discussed.
选择反应监测 (SRM) - 也称为多重反应监测 (MRM) - 已成为一种有前途的高通量靶向蛋白质定量技术,可用于候选生物标志物验证和系统生物学应用。然而,当前 SRM 技术的一个主要瓶颈是灵敏度不足,例如,检测人血浆或血清中可能存在的低丰度生物标志物(低至 ng/mL 至 pg/mL 范围内),或细胞或组织中极低丰度的信号蛋白。本文综述了近年来在方法和技术方面的进展,包括前端免疫亲和去除、分级、目标蛋白质/肽的选择性富集,包括翻译后修饰,以及 MS 仪器方面的进展,这些进展显著提高了 SRM 分析的整体灵敏度,并能够在人血浆或血清中检测到低至亚 ng/mL 水平的低丰度蛋白质。还讨论了在血浆中检测 pg/mL 水平蛋白质的足够灵敏度的潜力。